Beta-thalassaemia - Pipeline Insight, 2021
This report can be delivered to the clients within 3-4 Business Days
DelveInsight’s, “Beta-thalassaemia - Pipeline Insight, 2021,” report provides comprehensive insights about 22+ companies and 22+ pipeline drugs in Beta-thalassaemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Beta-thalassaemia: Overview
Beta thalassemia is an inherited blood disorder characterized by reduced levels of functional hemoglobin. Hemoglobin is found in red blood cells; it is the red, iron-rich, oxygen-carrying pigment of the blood. A main function of red blood cells is to deliver oxygen throughout the body. Beta thalassemia has three main forms – minor, intermedia and major, which indicate the severity of the disease. Individuals with beta thalassemia minor usually do not have any symptoms (asymptomatic) and individuals often are unaware that they have the condition. Some individuals do experience a very mild anemia. Individuals with beta thalassemia major have a severe expression of the disorder; they often require regular blood transfusions and lifelong, ongoing medical care. The symptoms of beta thalassemia intermedia are widely variable and severity falls in the broad range between the two extremes of the major and minor forms. The characteristic finding of beta thalassemia is anemia, which is caused because red blood cells are abnormally small (microcytic), are not produced at the normal amounts, and do not contain enough functional hemoglobin.
'Beta-thalassaemia - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Beta-thalassaemia pipeline landscape is provided which includes the disease overview and Beta-thalassaemia treatment guidelines. The assessment part of the report embraces, in depth Beta-thalassaemia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Beta-thalassaemia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Beta-thalassaemia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Beta-thalassaemia Emerging Drugs
Further product details are provided in the report……..
Beta-thalassaemia: Therapeutic Assessment
This segment of the report provides insights about the different Beta-thalassaemia drugs segregated based on following parameters that define the scope of the report, such as:
Beta-thalassaemia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Beta-thalassaemia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Beta-thalassaemia drugs.
Beta-thalassaemia Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Beta-thalassaemia - Pipeline Insight, 2021,” report provides comprehensive insights about 22+ companies and 22+ pipeline drugs in Beta-thalassaemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Beta-thalassaemia: Overview
Beta thalassemia is an inherited blood disorder characterized by reduced levels of functional hemoglobin. Hemoglobin is found in red blood cells; it is the red, iron-rich, oxygen-carrying pigment of the blood. A main function of red blood cells is to deliver oxygen throughout the body. Beta thalassemia has three main forms – minor, intermedia and major, which indicate the severity of the disease. Individuals with beta thalassemia minor usually do not have any symptoms (asymptomatic) and individuals often are unaware that they have the condition. Some individuals do experience a very mild anemia. Individuals with beta thalassemia major have a severe expression of the disorder; they often require regular blood transfusions and lifelong, ongoing medical care. The symptoms of beta thalassemia intermedia are widely variable and severity falls in the broad range between the two extremes of the major and minor forms. The characteristic finding of beta thalassemia is anemia, which is caused because red blood cells are abnormally small (microcytic), are not produced at the normal amounts, and do not contain enough functional hemoglobin.
'Beta-thalassaemia - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Beta-thalassaemia pipeline landscape is provided which includes the disease overview and Beta-thalassaemia treatment guidelines. The assessment part of the report embraces, in depth Beta-thalassaemia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Beta-thalassaemia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Beta-thalassaemia R&D. The therapies under development are focused on novel approaches to treat/improve Beta-thalassaemia.
This segment of the Beta-thalassaemia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Beta-thalassaemia Emerging Drugs
- CTX001: CRISPR Therapeutics
- IMR-687: Imara, Inc.
Further product details are provided in the report……..
Beta-thalassaemia: Therapeutic Assessment
This segment of the report provides insights about the different Beta-thalassaemia drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Beta-thalassaemia
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravenous
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Beta-thalassaemia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Beta-thalassaemia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Beta-thalassaemia drugs.
Beta-thalassaemia Report Insights
- Beta-thalassaemia Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Beta-thalassaemia drugs?
- How many Beta-thalassaemia drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Beta-thalassaemia?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Beta-thalassaemia therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Beta-thalassaemia and their status?
- What are the key designations that have been granted to the emerging drugs?
- CRISPR Therapeutics
- Imara, Inc.
- Sangamo Therapeutics
- Vifor Pharma
- Bioray Laboratories
- EdiGene (GuangZhou) Inc.
- Ionis Pharmaceuticals, Inc.
- Agios Pharmaceuticals, Inc.
- Silence Therapeutics plc
- Aruvant Sciences
- Phoenicia Biosciences
- San Rocco Therapeutics
- Shanghai BDgene
- Beam Therapeutics
- EmeraMed
- Regenacy Pharmaceuticals
- Editas Medicine
- Fulcrum Therapeutics
- Allife Medical Science and Technology
- Global Blood Therapeutics, Inc
- Orchard Therapeutics
- Acceleron Pharma
- Disc Medicine
- CTX001
- IMR-687
- ST-400
- luspatercept-aamt
- VIT-2763
- OTL-300
- ?-globin restored autologous HSC
- BEAM 101
- Emeramide
- FTX 6058
- EDIT 301
- CRISPR/Cas9 modified human haematopoietic stem cell therapy
- Research programme: HDAC1/2 inhibitors
- ET-01
- IONIS TMPRSS6-LRx
- Mitapivat
- SLN124
- ARU 1801
- PB 04
- Beta globin transduced bone marrow cells
- BD 211
- DISC a
Introduction
Executive Summary
Beta-thalassaemia: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Beta-thalassaemia – DelveInsight’s Analytical Perspective
Mid Stage Products (Phase II)
Comparative Analysis
IMR-687: Imara, Inc.
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early Stage Products (Phase I)
Comparative Analysis
BD 211: Shanghai BDgene
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Preclinical and Discovery Stage Products
Comparative Analysis
DISC a: Disc Medicine
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Beta-thalassaemia Key Companies
Beta-thalassaemia Key Products
Beta-thalassaemia- Unmet Needs
Beta-thalassaemia- Market Drivers and Barriers
Beta-thalassaemia- Future Perspectives and Conclusion
Beta-thalassaemia Analyst Views
Beta-thalassaemia Key Companies
Appendix
Executive Summary
Beta-thalassaemia: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Beta-thalassaemia – DelveInsight’s Analytical Perspective
Mid Stage Products (Phase II)
Comparative Analysis
IMR-687: Imara, Inc.
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early Stage Products (Phase I)
Comparative Analysis
BD 211: Shanghai BDgene
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Preclinical and Discovery Stage Products
Comparative Analysis
DISC a: Disc Medicine
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Beta-thalassaemia Key Companies
Beta-thalassaemia Key Products
Beta-thalassaemia- Unmet Needs
Beta-thalassaemia- Market Drivers and Barriers
Beta-thalassaemia- Future Perspectives and Conclusion
Beta-thalassaemia Analyst Views
Beta-thalassaemia Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Beta-thalassaemia
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Beta-thalassaemia
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Beta-thalassaemia
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Beta-thalassaemia
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products